Galapagos NV (NASDAQ:GLPG)
| 55.33 Delayed Data As of Sep 16 |  -0.17 / -0.31%Today’s Change | 54.55 Today|||52-Week Range 148.68 | -44.10% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $3.8B |
Company Description
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Contact Information
Galapagos NV Industriepark Mechelen Noord Mechelen Brussels Region 2800 |
Employees
Shareholders
| Other institutional | 7.02% |
| Mutual fund holders | 4.20% |
| Individual stakeholders | -- |
Top Executives
| Onno van de Stolpe | Chief Executive Officer |
| Bart Filius | President & Chief Operating Officer |
| Piet Wigerinck | Chief Scientific Officer |
| Walid Abi-Saab | Chief Medical Officer |
| Andre Hoekema | Chief Business Officer |
